Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Calderasib

Copy Product Info
😃Good
Catalog No. T86905Cas No. 2641216-67-1
Alias MK-1084, MK1084

Calderasib (MK-1084) is a selective KRAS G12C inhibitor with an IC50 value of 1.2 nM . Calderasib (MK-1084) exhibits significant anticancer activity, and it can be employed either as a monotherapy or in combination with the PD-1 inhibitor Pembrolizumab, providing a versatile approach for the investigation of KRAS-mutant driven cancers.

Calderasib

Calderasib

Copy Product Info
😃Good
Purity: 98.69%
Catalog No. T86905Alias MK-1084, MK1084Cas No. 2641216-67-1
Calderasib (MK-1084) is a selective KRAS G12C inhibitor with an IC50 value of 1.2 nM . Calderasib (MK-1084) exhibits significant anticancer activity, and it can be employed either as a monotherapy or in combination with the PD-1 inhibitor Pembrolizumab, providing a versatile approach for the investigation of KRAS-mutant driven cancers.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$943-In Stock
5 mg$2,360-In Stock
10 mg$3,550-In Stock
25 mg$6,780-In Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:98.69%
Appearance:Solid
Color:Yellow
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
Calderasib (MK-1084) is a selective KRAS G12C inhibitor with an IC50 value of 1.2 nM . Calderasib (MK-1084) exhibits significant anticancer activity, and it can be employed either as a monotherapy or in combination with the PD-1 inhibitor Pembrolizumab, providing a versatile approach for the investigation of KRAS-mutant driven cancers.
In vitro
Calderasib (MK-1084) (0.01-10 μM, 2 h) inhibited the phosphorylation of ERK1/2 in H358 cells with an IC50 of 9 nM. [2]
In vivo
Calderasib (MK-1084) (10-30 mg/kg, administered orally for 14 consecutive days) was given to the MiaPaCa-2 xenograft mouse model, and the Results demonstrated that Calderasib (MK-1084) significantly inhibited tumor growth.[2]
SynonymsMK-1084, MK1084
Chemical Properties
Molecular Weight637.08
FormulaC32H31ClF2N6O4
Cas No.2641216-67-1
SmilesO=C1N2C=3C(C(=N1)N4C(C)CN(C(C=C)=O)C(C)C4)=CC(Cl)=C(N3)C=5C(=C(F)C=CC5F)OCCOC=6C2=C(C(C)C)N=CC6
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 80 mg/mL (125.57 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM1.5697 mL7.8483 mL15.6966 mL78.4831 mL
5 mM0.3139 mL1.5697 mL3.1393 mL15.6966 mL
10 mM0.1570 mL0.7848 mL1.5697 mL7.8483 mL
20 mM0.0785 mL0.3924 mL0.7848 mL3.9242 mL
50 mM0.0314 mL0.1570 mL0.3139 mL1.5697 mL
100 mM0.0157 mL0.0785 mL0.1570 mL0.7848 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy Calderasib | purchase Calderasib | Calderasib cost | order Calderasib | Calderasib chemical structure | Calderasib in vivo | Calderasib in vitro | Calderasib formula | Calderasib molecular weight